Low thyroid function is associated with nonalcoholic fatty liver disease and predicted all-cause and cardiovascular mortality in this population.
Women with non-alcoholic fatty liver disease have increased risks for maternal and neonatal complications.
First responders to the World Trade Center attacks appear to have a much higher prevalence of hepatic steatosis than the general population.
The FDA has granted Fast Track designation to intravenous choline chloride (Protara Therapeutics), an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure-associated liver disease.
Women have a lower overall risk of acquiring nonalcoholic fatty liver disease (NAFLD) than men do, but a higher risk of advanced fibrosis if NAFLD status is confirmed.
The lack of standardized diet and exercise recommendations across NAFLD/NASH clinical trials has posed a significant challenge in understanding their impact.
The first guidelines for assessing the eligibility of patients with NASH for inclusion in clinical studies were released.
The clinical burden associated with nonalcoholic fatty liver disease is high.
Experts proposed new guidelines on the diagnosis of metabolic-associated fatty liver disease (MAFLD), formerly non-alcohol fatty liver disease (NAFLD).
Increased blood glucose levels, even within the nondiabetic range, are associated with increased risk for nonalcoholic fatty liver disease.
Noninvasive scoring systems have modest predictive ability to identify the future development of severe liver disease in patients in the general population.
Nonalcoholic steatohepatitis (NASH) is expected to pose a significant clinical and economic burden during the next 20 years for U.S. patients with type 2 diabetes mellitus.
In this prospective study of patients with biopsy-proven NAFLD, daily aspirin use was associated with less severe histologic features of NAFLD and NASH, and with lower risk for progression to advanced fibrosis.
Findings of the analysis also revealed that some evidence indicates that liraglutide improves liver fat, liver function, and HbA1c, and may aid in NASH resolution and weight reduction.
The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application (NDA) for obeticholic acid (Intercept) for the treatment of fibrosis due to nonalcoholic steatohepatitis (NASH).
Carbohydrate quality in diet may play a potential role in improvement of hepatic fat mass and ALT level in NAFLD.
Whether single or additive, obesity is a significant risk factor for chronic liver disease.
Investigators aimed to evaluate the safety and tolerability of ubrogepant, focusing on hepatic safety, when administered intermittently with high-frequency dosing in healthy participants.
Tesamorelin significantly reduced hepatic fat fraction compared with placebo
The FDA has granted Fast Track designation to lanifibranor (Inventiva) for the treatment of non-alcoholic steatohepatitis.